BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
about
Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assaysDevelopment of venetoclax for therapy of lymphoid malignancies.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis.Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment.Close encounter of the covalent kind: Inhibiting MCL1's proapoptotic activity with covalent inhibitors.JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer.Targeting apoptosis in acute myeloid leukaemia.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.RNA Polymerase Tags To Monitor Multidimensional Protein-Protein Interactions Reveal Pharmacological Engagement of Bcl-2 Proteins.Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer.Pathways and mechanisms of venetoclax resistance.Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma.Comprehensive analysis of the clinical significance and prospective molecular mechanisms of differentially expressed autophagy-related genes in thyroid cancer.AT 101 induces early mitochondrial dysfunction and HMOX1 (heme oxygenase 1) to trigger mitophagic cell death in glioma cells.Overexpression of MYCT1 Inhibits Proliferation and Induces Apoptosis in Human Acute Myeloid Leukemia HL-60 and KG-1a Cells andIdentifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducersSystematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivityHigh PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patientsCharacterisation of the Morphological, Functional and Molecular Changes in Sunitinib-Resistant Renal Cell Carcinoma Cells
P2860
Q28077848-AC365EAF-B074-404C-8FCB-2BA2691143B2Q37702281-5B4D0438-9BFB-40C2-A301-FBD245BACDC9Q38664735-3C579E7D-5F8C-4350-BC3E-8B0741960B97Q38721725-8C896FF7-FB00-4D63-86AC-421D4DC469A8Q39267135-7E0A12A4-7F11-4125-B49D-FD499415E052Q42328732-28A663B2-8034-4D78-8AF9-9246C3C982CEQ44268034-C932ADE8-BFA1-4AC8-ACE4-9DDE6CA8BD72Q44489428-F71D755C-1477-465E-8084-86713E7E07DDQ46370948-708D73EA-E450-4FF8-BB08-E3B4CCA12860Q47853163-2E56C286-2A6E-4B14-8A0D-05C26CBC4171Q50911306-0B4A1860-A1A8-4A00-9035-67BA9ACD6479Q51160342-A88F85F0-AEE8-4219-ACA6-AA28EE32D3D2Q52571263-7C53A3D6-7112-48B4-B5CC-491F4DB6B73FQ55365028-EDDE784D-9D7C-4572-B843-0ED18B89CCB4Q55456768-40ED7487-57EA-4736-9DF8-473FA5D11B3CQ57073789-A74A5429-22B2-440D-9CA3-ECACB0B4655FQ57174958-C66A066F-2DCC-4D6C-BA23-D87FCA16EBF2Q58695490-59E6B8C3-DDE0-4CC9-8F7A-88EA626B33EEQ58700394-6E30ACA2-5E23-4E5C-9A5F-F778457301D6Q58790703-FD9BDC1B-C7F5-4419-957F-DC44345E499D
P2860
BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
@de
BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
@en
type
label
BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
@de
BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
@en
prefLabel
BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
@de
BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
@en
P2860
P1476
BCL2 Inhibitors as Anticancer Drugs: A Plethora of Misleading BH3 Mimetics.
@en
P2093
Alan Eastman
Ryan S Soderquist
P2860
P304
P356
10.1158/1535-7163.MCT-16-0031
P577
2016-08-17T00:00:00Z